Поражение затылочных отделов головного мозга: некоторые клинические, патогенетические и терапевтические особенности
https://doi.org/10.21518/2079-701X-2016-4-36-41
Аннотация
Об авторе
И. В. ДамулинРоссия
Список литературы
1. Brazis PW, Masdeu JC, Biller J. Localization in Clinical Neurology. 5th edition. Chennai etc.: Lippincott Williams & Wilkins, 2007. 168 p.
2. Rowe F. Visual fields via the visual pathway. Oxford etc.: Blackwell Publishing Ltd, 2006. 283 p.
3. Van Hooser SD. Similarity and diversity in visual cortex: is there a unifying theory of cortical computation? The Neuroscientist, 2007, 13(6): 639-656. doi.org/10.1177/1073858407306597.
4. Barton JJS. Disorder of higher visual function. Current Opinion in Neurology, 2011, 24: 1-5. doi. org/10.1097/wco.0b013e328341a5c2.
5. Braddick O, Atkinson J. Development of human visual function. Vision Research, 2011, 51: 15881609. doi.org/10.1016/j.visres.2011.02.018
6. De Renzi E. Disorders of visual recognition. Seminars in Neurology, 2000, 20(4): 479-485. doi.org/10.1055/s-2000-13181.
7. Barton JJS. Disorders of color and object recognition. CONTINUUM: Lifelong Learning in Neurology, 2010, 16(4): 111-127. doi. org/10.1212/01.con.0000368264.61286.9b
8. Clavagnier S, Prado J, Kennedy H, Perenin M-T. How humans reach: distinct cortical systems for central and peripheral vision. The Neuro-scientist, 2007, 13(1): 22-27. org/10.1177/1073858406295688.
9. Detre J.A., Floyd T.F. Functional MRI and its applications to the clinical neurosciences. The Neuroscientist, 2001, 7(1): 64-79. doi. org/10.1177/107385840100700110.
10. Klein S, Smolka MN, Wrase J. The influence of gender and emotional valence of visual cues on fMRI activation in humans. Pharmacopsychiatry, 2003, 36(suppl.3): 191-194. doi.org/10.1055/s-2003-45129.
11. He BJ, Shulman GL, Snyder AZ, Corbetta M. The role of impaired neuronal communication in neurological disorders. Current Opinion in Neurology, 2007, 20: 655-660. doi.org/10.1097/ wco.0b013e3282f1c720.
12. Adolphs R. Recognizing emotion from facial expressions: psychological and neurological mechanisms. Behavioral and Cognitive Neuroscience Reviews, 2002, 1(1): 21-62. doi.org/ 10.1177/1534582302001001003.
13. Rizzo M. Clinical assessment of complex visual dysfunction. Seminars in Neurology, 2000, 20(1): 75-87. doi.org/10.1055/s-2000-6834
14. Ribai P, Vokaer M, De Tiege X, Massat I, Slama H, Bier JC. Acute Balint's syndrome is not always caused by a stroke. European Journal of Neurology, 2006, 13: 310-312. doi.org/10.1111/ j.1468-1331.2006.01144.x
15. Rizzo M, Vecera SP. Psychoanatomical substrates of Balint's syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 2002, 72: 162-178. doi.org/10.1136/jnnp.72.2.162.
16. Ricciardi E, Pietrini P. New light from the dark: what blindness can teach us about brain function. Current Opinion in Neurology, 2011, 24: 357363. doi.org/10.1097/wco.0b013e328348bdbf.
17. Grossberg S. How does the cerebral cortex work? Development, learning, attention, and 3-D vision by laminar circuits of visual cortex. Behavorial and Cognitive Neuroscience Reviews, 2003, 2(1): 47-76. doi.org/10.1177/1534582303002001003.
18. Barrett BT, Bradley A, McGraw PV. Understanding the neural basis of amblyopia. The Neuroscientist, 2004, 10(2): 106-117. doi.org/10.1177/1073858403262153.
19. Lienhard GE, Slot JW, James DE, Mueckler MM. Glucose-Transportproteine. Spektrum der Wissenschaft, 1992, 14: 48-54.
20. Machicao F, Mushack J, Seffer E. Mannose, glu-cosamine and inositol monophosphate inhibit the effect of insulin on lipogenesis. Biochemical Journal, 1990, 266: 909-916.
21. Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. Journal of Cellular Physiology, 1991, 146: 148-155. doi. org/10.1002/jcp.1041460119.
22. Kanowski S, Kinzler E, Lehmann E, Schweizer A, Kuntz G. Confirmed clinical efficacy of Acto-vegin in elderly patients with organic brain syndrome. Pharmacopsychiatry, 1995, 28(4): 125-133. doi.org/10.1055/s-2007-979604.
23. Kinzler E, Lehmann E, Groth J, Heinrich K. Acto-vegin in der Behandlung geriatrischer Patienten mit hirnorganischem psychosyndrom. Munchen Medizinische Wochenschrift, 1988, 130: 644-646.
24. Oswald WD, Steger W, Oswald B, Kuntz G. Die Verbesserung fluider kognitiver Leistungen als Indikator fur die klinische Wirksamkeit einer nootropen Substanz. Eine placebokontrollierte Doppelblind-Studie mit Actovegin. Geronto-psychologie & Psychiatrie, 1991, 4: 209-220.
25. Oswald WD, Steger W, Oswald B, Kuntz G. Die Verbesserung fluider kognitiver Leistungen mit Actovegin-Infusionen bei Alterspatienten mit leichtem bis mittelschwerem organischem Psychosyndrom. Gerontopsychologie & Psychiatrie, 1992, 5: 251-266.
26. Guekht A, Skoog I, Korczin AD, Zakharov VV, Eeg M, Vigonius U. A randomized double blind placebo controlled trial of actovegin in patients with post stroke cognitive impairment ARTEMIDA study design. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3(1): 459-467. doi.org/10.1159/000357122.
Рецензия
Для цитирования:
Дамулин ИВ. Поражение затылочных отделов головного мозга: некоторые клинические, патогенетические и терапевтические особенности. Медицинский Совет. 2016;(4):36-41. https://doi.org/10.21518/2079-701X-2016-4-36-41
For citation:
Damulin IV. Occipital lobe lesions: some clinical, pathogenic and therapeutic features. Meditsinskiy sovet = Medical Council. 2016;(4):36-41. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-36-41